Treating acute myeloid leukemia (AML) is notoriously difficult due to its complex and varied nature. AML lacks a single, consistent target that is unique to cancer cells and absent from healthy ones. Many potential targets, such as proteins on AML cells, are also found on normal cells, making it challenging to attack the cancer without harming the patient’s healthy tissue. This overlap limits the effectiveness of traditional therapies, including antibody-based treatments and cell-based approaches.

Chimeric antigen receptor (CAR) T-cell therapies have shown remarkable success in some cancers, but they struggle in AML. The process requires collecting a patient’s own T cells, genetically modifying them to recognize cancer, and reinfusing them—a time-intensive procedure that can be too slow for a fast-moving disease like AML. Moreover, AML patients often have weakened or dysfunctional T cells, which complicates the therapy’s production and effectiveness.

Natural killer (NK) cells provide a promising alternative. Unlike T cells, NK cells can be sourced from healthy donors and engineered with CARs to target cancer, enabling an “off-the-shelf” treatment that doesn’t rely on the patient’s own immune cells. NK cells also tend to cause fewer immune-related side effects, making them an attractive option for therapy development.

SENTI-202 is a CAR-NK cell therapy designed specifically to tackle AML’s targeting challenges. It uses NK cells engineered to recognize two proteins commonly found on AML cells: CD33 and FLT3. By focusing on two targets instead of one, SENTI-202 aims to address AML’s heterogeneity, ensuring it can attack a broader range of cancer cells that express either or both of these markers.

What sets SENTI-202 apart is its logic-gating mechanism, a sophisticated system that balances activation and inhibition to improve targeting accuracy.

The CAR component of the NK cells is programmed to activate when it detects CD33 or FLT3 on a cell’s surface, prompting an attack.

However, an inhibitory receptor acts as a “safety switch.” If a cell expresses EMCN—a protein found on healthy hematopoietic stem cells—in addition to CD33 or FLT3, the NK cells are prevented from attacking.

This dual-signal approach mimics a logical “AND NOT” gate: the therapy kills cells that have CD33/FLT3 and not EMCN, effectively sparing healthy cells while targeting cancerous ones.

Beyond AML, this approach could inspire similar strategies for other cancers where distinguishing malignant cells from healthy ones remains a barrier. SENTI-202 showcases how innovative engineering can redefine targeted therapy, offering hope for more effective and tailored cancer treatments in the future.

Source.